Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | BACE1 | P56817 | 12/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460433 | 0.86 | AKT1 (0.44) | AKT1CA2BACE1BACE2 | |
| SCHEMBL23983014 | 0.81 | HTT (0.38) | AKT1 | |
| SCHEMBL23983089 | 0.81 | HTT (0.38) | AKT1 | |
| Hydrochloric Acid SCHEMBL23113767 | 0.80 | HTT (0.37) | AKT1 | |
| Hydrochloric Acid SCHEMBL31441168 | 0.80 | HTT (0.37) | AKT1 | |
| SCHEMBL23983044 | 0.79 | GRPR (0.38) | AKT1 | |
| Trifluoroacetic Acid SCHEMBL29460421 | 0.79 | AKT1 (0.40) | AKT1 | |
| Trifluoroacetic Acid SCHEMBL31441167 | 0.79 | AKT1 (0.36) | AKT1 | |
| Trifluoroacetic Acid SCHEMBL23113768 | 0.79 | AKT1 (0.36) | AKT1 | |
| SCHEMBL22648530 | 0.78 | CTSS (0.60) | CTSSCTSKCA2BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20220096653-A1 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | ASTELLAS PHARMA INC. (JP) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | AKT1 4878/4885CTSS 1163/4885CTSK 902/4885 |
| US-20220096653-A1 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | SIGLEC7, TNFSF11, FCGR2A | AKT1 4860/4885CTSS 2536/4885CTSK 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.